Nadia Haddy1, Stéphanie Diallo2, Chiraz El-Fayech2, Boris Schwartz2, François Pein2, Mike Hawkins2, Cristina Veres2, Odile Oberlin2, Catherine Guibout2, Hélène Pacquement2, Martine Munzer2, Tan Dat N'Guyen2, Pierre-Yves Bondiau2, Delphine Berchery2, Anne Laprie2, Pierre-Yves Scarabin2, Xavier Jouven2, André Bridier2, Serge Koscielny2, Eric Deutsch2, Ibrahima Diallo2, Florent de Vathaire2. 1. From Radiation Epidemiology Group, INSERM, UMR1018, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., S.K., I.D., F.d.V.); Gustave Roussy, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., A.B., S.K., E.D., I.D., F.d.V.); Université Paris XI, Villejuif, France (N.H., C.E.-F., B.S., C.V., C.G., I.D., F.d.V.); Centre Hospitalier de Gonesse, Service Pharmacie, Gonesse, France (S.D.); Institut de Cancérologie de l'Ouest, site René Gauducheau CLCC Nantes-Atlantique, Département de Recherche, Saint-Herblain, France (F.P.); Centre for Childhood Cancer Survivor Studies, Department of Public Health & Epidemiology, University of Birmingham, United Kingdom (M.H.); Institut Curie, Paris, France (H.P.); CHU de Reims, Reims, France (M.M.); Institut Jean Godinot, Reims, France (T.D.N'G.); Centre Antoine Lacassagne, Nice, France (P.-Y.B.); Centre Claudius Régaud, Toulouse, France (D.B., A.L.); UMR 1018, University of Paris XI, Villejuif, France (P.-Y.S.); and INSERM U 970, Paris, France (X.J.). nadia.haddy@gustaveroussy.fr. 2. From Radiation Epidemiology Group, INSERM, UMR1018, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., S.K., I.D., F.d.V.); Gustave Roussy, Villejuif, France (N.H., C.E.-F., B.S., C.V., O.O., C.G., A.B., S.K., E.D., I.D., F.d.V.); Université Paris XI, Villejuif, France (N.H., C.E.-F., B.S., C.V., C.G., I.D., F.d.V.); Centre Hospitalier de Gonesse, Service Pharmacie, Gonesse, France (S.D.); Institut de Cancérologie de l'Ouest, site René Gauducheau CLCC Nantes-Atlantique, Département de Recherche, Saint-Herblain, France (F.P.); Centre for Childhood Cancer Survivor Studies, Department of Public Health & Epidemiology, University of Birmingham, United Kingdom (M.H.); Institut Curie, Paris, France (H.P.); CHU de Reims, Reims, France (M.M.); Institut Jean Godinot, Reims, France (T.D.N'G.); Centre Antoine Lacassagne, Nice, France (P.-Y.B.); Centre Claudius Régaud, Toulouse, France (D.B., A.L.); UMR 1018, University of Paris XI, Villejuif, France (P.-Y.S.); and INSERM U 970, Paris, France (X.J.).
Abstract
BACKGROUND: Cardiac disease (CD) is one of the major side effects of childhood cancer therapy, but until now little has been known about the relationship between the heart radiation dose (HRD) received during childhood and the risk of CD. METHODS AND RESULTS: The cohort comprised 3162 5-year survivors of childhood cancer. Chemotherapy information was collected and HRD was estimated. There were 347 CDs in 234 patients, 156 of them were rated grade ≥3. Cox and Poisson regression models were used. The cumulative incidence of any type of CD at 40 years of age was 11.0% (95% confidence interval [CI], 9.5-12.7) and 7·4% (95% CI, 6.2-8.9) when only the CDs of grade ≥3 were considered. In comparison with patients who received no anthracycline and either no radiotherapy or an HRD<0·1Gy, the risk was multiplied by 18·4 (95% CI, 7.1-48.0) in patients who had received anthracycline and no radiotherapy or a HRD <0.1Gy, by 60.4 (95% CI, 22.4-163.0) in those who had received no anthracycline and an HRD≥30Gy, and 61.5 (95% CI, 19.6-192.8) in those who had received both anthracycline and an HRD≥30Gy. CONCLUSIONS: Survivors of childhood cancers treated with radiotherapy and anthracycline run a high dose-dependent risk of developing CD. CDs develop earlier in patients treated with anthracycline than in those treated without it.
BACKGROUND:Cardiac disease (CD) is one of the major side effects of childhood cancer therapy, but until now little has been known about the relationship between the heart radiation dose (HRD) received during childhood and the risk of CD. METHODS AND RESULTS: The cohort comprised 3162 5-year survivors of childhood cancer. Chemotherapy information was collected and HRD was estimated. There were 347 CDs in 234 patients, 156 of them were rated grade ≥3. Cox and Poisson regression models were used. The cumulative incidence of any type of CD at 40 years of age was 11.0% (95% confidence interval [CI], 9.5-12.7) and 7·4% (95% CI, 6.2-8.9) when only the CDs of grade ≥3 were considered. In comparison with patients who received no anthracycline and either no radiotherapy or an HRD<0·1Gy, the risk was multiplied by 18·4 (95% CI, 7.1-48.0) in patients who had received anthracycline and no radiotherapy or a HRD <0.1Gy, by 60.4 (95% CI, 22.4-163.0) in those who had received no anthracycline and an HRD≥30Gy, and 61.5 (95% CI, 19.6-192.8) in those who had received both anthracycline and an HRD≥30Gy. CONCLUSIONS: Survivors of childhood cancers treated with radiotherapy and anthracycline run a high dose-dependent risk of developing CD. CDs develop earlier in patients treated with anthracycline than in those treated without it.
Authors: James E Bates; Christopher Klassen; Savas Ozdemir; Stella Flampouri; Robert Percy; Nancy P Mendenhall; Bradford S Hoppe Journal: Int J Part Ther Date: 2019-05-07
Authors: Eric J Chow; Yan Chen; Melissa M Hudson; Elizabeth A M Feijen; Leontien C Kremer; William L Border; Daniel M Green; Lillian R Meacham; Daniel A Mulrooney; Kirsten K Ness; Kevin C Oeffinger; Cécile M Ronckers; Charles A Sklar; Marilyn Stovall; Helena J van der Pal; Irma W E M van Dijk; Flora E van Leeuwen; Rita E Weathers; Leslie L Robison; Gregory T Armstrong; Yutaka Yasui Journal: J Clin Oncol Date: 2017-11-02 Impact factor: 44.544
Authors: Marjan Boerma; Vijayalakshmi Sridharan; Xiao-Wen Mao; Gregory A Nelson; Amrita K Cheema; Igor Koturbash; Sharda P Singh; Alan J Tackett; Martin Hauer-Jensen Journal: Mutat Res Rev Mutat Res Date: 2016-07-10 Impact factor: 5.657
Authors: James E Bates; Rebecca M Howell; Qi Liu; Yutaka Yasui; Daniel A Mulrooney; Sughosh Dhakal; Susan A Smith; Wendy M Leisenring; Daniel J Indelicato; Todd M Gibson; Gregory T Armstrong; Kevin C Oeffinger; Louis S Constine Journal: J Clin Oncol Date: 2019-03-12 Impact factor: 44.544
Authors: Suman Shrestha; Aashish C Gupta; James E Bates; Choonsik Lee; Constance A Owens; Bradford S Hoppe; Louis S Constine; Susan A Smith; Ying Qiao; Rita E Weathers; Yutaka Yasui; Laurence E Court; Arnold C Paulino; Chelsea C Pinnix; Stephen F Kry; David S Followill; Gregory T Armstrong; Rebecca M Howell Journal: Radiother Oncol Date: 2020-10-17 Impact factor: 6.280
Authors: E A M Lieke Feijen; Anna Font-Gonzalez; Helena J H Van der Pal; Wouter E M Kok; Ronald B Geskus; Cécile M Ronckers; Dorine Bresters; Elvira C van Dalen; Eline van Dulmen-den Broeder; Marleen H van den Berg; Margriet van der Heiden-van der Loo; Marry M van den Heuvel-Eibrink; Flora E van Leeuwen; Jacqueline J Loonen; Sebastian J C M M Neggers; A B Birgitta Versluys; Wim J E Tissing; Leontien C M Kremer Journal: J Am Heart Assoc Date: 2019-01-08 Impact factor: 5.501
Authors: Chelsea R Stone; Alexis T Mickle; Devon J Boyne; Aliya Mohamed; Doreen M Rabi; Darren R Brenner; Christine M Friedenreich Journal: Health Sci Rep Date: 2019-08-13